LUCD · Insider Trading
Lucid Diagnostics Inc. Common Stock
Every open-market purchase and sale reported by LUCD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-21 | Dennis Matheis | Director | Buy | +245,000 | +$245.27K |
| 2026-02-24 | Jacque J Sokolov | Director | A | +123,000 | — |
| 2026-02-24 | Dennis Matheis | Director | A | +123,000 | — |
| 2026-02-24 | Stanley Lapidus | Director | A | +123,000 | — |
| 2026-02-24 | John R Palumbo | Director | A | +123,000 | — |
| 2026-02-24 | Shaun O'Neil | President and COO | A | +620,000 | — |
| 2026-02-24 | Lishan Aklog | Chief Executive Officer | A | +2,170,000 | — |
| 2026-02-24 | Michael Adam Gordon | General Counsel and Secretary | A | +300,000 | — |
| 2026-02-24 | Debra White | Director | A | +123,000 | — |
| 2026-02-24 | Dennis M McGrath | Chief Financial Officer | A | +470,000 | — |
| 2026-02-24 | James L Cox | Director | A | +123,000 | — |
| 2026-02-24 | Ronald M Sparks | Director | A | +123,000 | — |
| 2025-10-07 | John R Palumbo | Director | A | +215,000 deriv. | — |
| 2025-08-22 | Dennis Matheis | Director | Buy | +100,000 | +$101.84K |
| 2025-05-23 | Dennis Matheis | Director | Buy | +350,000 | +$457.61K |
| 2025-05-22 | Dennis Matheis | Director | Buy | +350,000 | +$457.61K |
| 2025-02-21 | Jacque J Sokolov | Director | A | +112,800 | — |
| 2025-02-21 | James L Cox | Director | A | +112,800 | — |
| 2025-02-21 | Ronald M Sparks | Director | A | +112,800 | — |
| 2025-02-21 | Debra White | Director | A | +112,800 | — |
| 2025-02-21 | Dennis M McGrath | Chief Financial Officer | A | +300,000 | — |
| 2025-02-21 | Michael Adam Gordon | General Counsel and Secretary | A | +300,000 | — |
| 2025-02-21 | Lishan Aklog | Chief Executive Officer | A | +300,000 | — |
| 2025-02-21 | Shaun O'Neil | President and COO | A | +300,000 | — |
| 2025-02-21 | Dennis Matheis | Director | A | +112,800 | — |
| 2025-02-21 | Stanley Lapidus | Director | A | +112,800 | — |
| 2024-05-09 | Dennis Matheis | Director | A | +241,500 deriv. | — |
| 2024-05-08 | Shaun O'Neil | President and COO | A | +400,000 | — |
| 2024-05-08 | Dennis M McGrath | Chief Financial Officer | A | +400,000 | — |
| 2024-05-08 | Lishan Aklog | Chief Executive Officer | A | +400,000 | — |
| 2024-05-08 | Michael Adam Gordon | General Counsel and Secretary | A | +400,000 | — |
| 2024-02-23 | Stanley Lapidus | Director | A | +150,000 deriv. | — |
| 2024-02-23 | Ronald M Sparks | Director | A | +150,000 deriv. | — |
| 2024-02-23 | James L Cox | Director | A | +150,000 deriv. | — |
| 2024-02-23 | Jacque J Sokolov | Director | A | +150,000 deriv. | — |
| 2024-02-23 | Debra White | Director | A | +150,000 deriv. | — |
| 2024-02-20 | PAVmed Inc. | 10%+ Owner | J | −3,331,747 | — |
| 2024-01-30 | PAVmed Inc. | 10%+ Owner | J | +3,331,771 | +$4.68M |
| 2023-09-27 | Stanley Lapidus | Director | Sell | −3,917 | −$5.67K |
| 2023-09-27 | Stanley Lapidus | Director | Sell | −29,947 | −$43.46K |
| 2023-09-22 | Stanley Lapidus | Director | Sell | −3,917 | −$5.67K |
| 2023-04-13 | PAVmed Inc. | 10%+ Owner | J | +3,375,230 | +$6.47M |
| 2023-02-02 | James L Cox | Director | A | +175,000 deriv. | — |
| 2023-02-02 | Debra White | Director | A | +175,000 deriv. | — |
| 2023-02-02 | Jacque J Sokolov | Director | A | +175,000 deriv. | — |
| 2023-02-02 | Stanley Lapidus | Director | A | +175,000 deriv. | — |
| 2023-02-02 | Ronald M Sparks | Director | A | +175,000 deriv. | — |
| 2022-12-02 | PAVmed Inc. | 10%+ Owner | J | +3,375,230 | +$6.47M |
| 2022-09-22 | Stanley Lapidus | Director | Sell | −33,864 | −$57.68K |
| 2022-08-02 | Debra White | Director | A | +80,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lishan Aklog | Chief Executive Officer | 3,636,627 | $1.49M |
| Dennis M McGrath | Chief Financial Officer | 1,813,569 | $745.38K |
| Shaun O'Neil | President and COO | 1,446,763 | $594.62K |
| Dennis Matheis | Director | 1,033,443 | $424.75K |
| Michael Adam Gordon | General Counsel and Secretary | 1,000,000 | $411.00K |
| James L Cox | Director | 405,120 | $166.50K |
| John R Palumbo | Director | 338,000 | $138.92K |
| Stanley Lapidus | Director | 337,392 | $138.67K |
| Jacque J Sokolov | Director | 320,460 | $131.71K |
| Ronald M Sparks | Director | 320,460 | $131.71K |
| Debra White | Director | 235,800 | $96.91K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LUCD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.